The Health Dangers of Visceral Fat: Causes, Risks, and Advanced Treatment Options Visceral fatoften referred to as "deep belly fat" or "beer belly"is more than just a cosmetic concern
By extrapolation from the established profiles of approved GLP-1 receptor agonists including semaglutide (Wegovy SmPC, MHRA/EMC) and tirzepatide (Mounjaro SmPC, MHRA/EMC) clinicians should anticipate the need to review and potentially reduce antihypertensive doses as significant weight loss occurs, in line with BNF and NICE guidance principles
Semaglutide helps many people with type 2 diabetes or weight loss
Glucagon-like peptide 1 receptor agonists (GLP1-RAs) like semaglutide, known for reducing cardiovascular outcomes, have shown promise in addressing these risks, even among patients with CKD and without diabetes
In laboratory environments, it is widely used for the preparation, reconstitution, and dilution of lyophilized peptides and other research compounds